Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Apr 25;3(2):e000693. doi: 10.1161/JAHA.113.000693

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2014 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

Figure 3. — The cardiomyogenic effect of CsA mainly resulted from mPTP inhibition rather than from calcineurin inhibition. A and B, Representative FACS analysis and the percentage of cTnT⁺ cardiomyocytes incubated with control vehicle (Con), CsA (2 μg/mL), NIM811 (3.6 μg/mL), FK506 (100 ng/mL) and a combination of NIM811 and FK506. C, Phase‐contrast image showing beating cardiomyocyte foci (black arrow head) incubated with Con, NIM811 and FK506. D, Comparison of the number of beating foci. E, Live cell images showing αMHC‐GFP⁺ cardiomyocytes. F, Percentage of αMHC‐GFP⁺ area in live cell image. All scale bars, 100 μm. *P<0.01, ^#P<0.05 and NS (not significant) vs Con or each group. CsA indicates cyclosporin A; cTnT, cardiac Troponin T; GFP, green fluorescent protein; MHC, myosin heavy chain; mPTP, mitochondrial permeability transition pore.